PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection
Version of Record online: 27 OCT 2009
© 2009 British HIV Association
Volume 10, Issue 10, pages 591–613, November 2009
How to Cite
PENTA Steering Committee (2009), PENTA 2009 guidelines for the use of antiretroviral therapy in paediatric HIV-1 infection. HIV Medicine, 10: 591–613. doi: 10.1111/j.1468-1293.2009.00759.x
- Issue online: 27 OCT 2009
- Version of Record online: 27 OCT 2009
- Accepted 25 June 2009
- 3World Health Organization. Antiretroviral Therapy for HIV Infection in Infants and Children: Towards Universal Access: Recommendations for a Public Health Approach. Geneva: World Health Organization, 2007.
- 4Working Group on Antiretroviral Therapy and Medical Management of HIV-Infected Children. Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Rockville, MD: National Institutes of Health, 2008.
- 9Centers for Disease Control and Prevention. 1994 revised classification system for human immunodeficiency virus infection in children less than 13 years of age. Morbid Mortal Wkly Rep 1994; 43 (RR-12): 1–10.
- 10World Health Organization. WHO Case Definitions of HIV for Surveillance, and Revised Clinical Staging and Immunological Classification of HIV Related Disease in Adults and Children. Geneva: World Health Organization, 2006.
- 13World Health Organization. Guidelines on Co-Trimoxazole Prophylaxis for HIV-related Infections Among Children, Adolescents and Adults: Recommendations for a Public Health Approach. Geneva: World Health Organization, 2006.
- 17Treating Opportunistic Infections in HIV-Infected Children. London: Children's HIV Association of the UK and Ireland, 2006. Available at: http://www.chiva.org.uk/protocols/supportdocs/pdfdocs/CHIVA-presubmissionAug06.pdf (accessed 2 September 2009).,
- 22HIV Paediatric Prognostic Markers Collaborative Study Group. Short-term risk of disease progression in HIV-1-infected children receiving no antiretroviral therapy or zidovudine monotherapy: a meta-analysis. Lancet 2003; 362: 1605–1611.
- 23HIV Paediatric Prognostic Markers Collaborative Study Group. Use of total lymphocyte count for informing when to start antiretroviral therapy in HIV-infected children: a meta-analysis of longitudinal data. Lancet 2005; 366: 1868–1874.
- 25SMART Study Group, INSIGHT. Major clinical outcomes in patients not treated with antiretroviral therapy at baseline in SMART: a rationale for a trial to examine early treatment of HIV disease. 4th IAS Conference on HIV Pathogenesis, Treatment, and Prevention. Sydney, Australia, July 2007 [Abstract WEPEB018].for the
- 40Impact of reverse transcriptase resistance on the efficacy of TMC125 (etravirine) with two nucleoside reverse transcriptase inhibitors in protease inhibitor-naïve, nonnucleoside reverse transcriptase inhibitor-experienced patients: Study TMC125-C227. HIV Med 2008; 9: 883–896., , et al.
- 45Treatment interruption in children with chronic HIV-infection: the results of the Paediatric European Network for Treatment of AIDS (PENTA) 11 Trial. J Int AIDS Soc 2008; 11 (Suppl 1): O21., , et al.